Direct answer. Heart disease in children includes structural defects present from birth and conditions affecting heart muscle, blood vessels or rhythm that can appear later. Assessment and treatment depend on the actual diagnosis and the child’s condition. Severe breathing difficulty, sudden blue or grey colour, collapse or reduced responsiveness needs emergency help. Feeding, growth, development and continuing care are part of cardiac care, not secondary concerns. NHS congenital heart disease, December11,2025; Evelina/Royal Brompton actual staff myocarditis/cardiomyopathy guideline, March2024 version1,2pages.
- A child can have heart disease without having a structural defect at birth.
- A passed newborn oxygen screen cannot rule out every critical congenital condition.
- Poor feeding, tiring during feeds or growth concerns deserve clinical assessment.
- Children’s medicines and activity plans need paediatric review.
- A childhood repair may still require continuing congenital care into adulthood.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Is every childhood heart condition congenital? | Clinical distinctions | No. Acquired inflammatory, muscle and rhythm problems also occur. |
| Does passing an oxygen screen exclude all serious defects? | Screening education | No. A normal result cannot explain away later illness. |
| Is slow growth only a food-quantity problem? | Feeding education | Not necessarily; workload and swallowing safety can need assessment. |
| Does a repair end all follow-up? | Continuing-care education | No universal rule; retain the diagnosis, procedures and review plan. |
| Can an adult medicine or exercise plan be copied? | Safety boundary | No. The child’s diagnosis, size, development and current stability matter. |
Confidence is high in the need for condition-specific assessment and urgent attention to warning signs; recommendations are attributed clinical context, not independently certified treatment effects. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Congenital defects and acquired childhood heart conditions
Congenital heart disease is a structural difference present from birth. It can involve a wall between chambers, a valve or the connections of major vessels. Some findings need observation; others need urgent intervention. “A hole in the heart” is too broad to explain the whole circulation. NHS congenital heart disease, December11,2025.
Acquired disease is different. Myocarditis involves heart-muscle inflammation; cardiomyopathy describes a muscle disorder. A critically unwell child may have poor feeding, fatigue, rhythm symptoms or circulatory instability. The actual2024 specialist staff source is used for these distinctions, not as a home treatment protocol. Evelina/Royal Brompton actual staff myocarditis/cardiomyopathy guideline, March2024 version1,2pages.
Kawasaki disease is another childhood condition that can affect the heart’s blood vessels. Persistent fever with concerning features needs clinical assessment. Its diagnosis is not made by a single test, and symptoms overlap with other illnesses. NHS Kawasaki disease, February19,2026.
A rhythm problem can occur at different ages, with or without a known structural defect. SVT is one example of an abnormally fast rhythm. Adult resting-pulse numbers should not be used as a universal diagnostic threshold for a baby or child. NHS SVT selected all-age rhythm context, June12,2024.
Assessment, heart tests and newborn screening limits
The first assessment asks which part of the heart or circulation is affected and how the child is coping. Symptoms alone do not map the anatomy or identify a rhythm. Tell the clinician about feeding, activity, growth and the timing of episodes rather than relying on a general label. NHLBI congenital diagnosis, March24,2022.
Echocardiography uses ultrasound to examine structure and function. An ECG records electrical activity. Selected imaging, catheter measurements or genetic investigation may answer additional questions. Different tests do different jobs; one normal result does not automatically settle every possible concern. NHLBI congenital diagnosis, March24,2022.
Newborn pulse-oximetry screening estimates oxygen levels and can flag possible critical disease. A low result can also have noncardiac causes. A passed screen does not exclude every critical defect, so a subsequently unwell baby still needs assessment. It is screening, not a complete anatomical diagnosis. CDC newborn cardiac screening explanation and limits, December15,2025.
Diagnosis may occur before birth, shortly afterward or later. Ask what is established, what remains uncertain and which findings the team plans to watch. A simplified drawing should be accompanied by an explanation of this child’s actual connections and any previous procedures. NHLBI congenital diagnosis, March24,2022.
Observation, structural treatment and specialist care
Observation is an active care decision when it is appropriate: it requires a review plan and an explanation of changes that would alter treatment. The fact that some defects need no immediate procedure is not permission to wait through severe symptoms. NHLBI selected congenital treatment categories, March24,2022.
Catheter procedures and operations address selected structural problems. A catheter can deliver certain treatments through a blood vessel, while surgery may alter or reconstruct the circulation. Suitability depends on anatomy and the clinical problem, rather than the promise of a smaller incision. NHLBI selected congenital treatment categories, March24,2022.
Some children need staged procedures or mechanical support. The purpose should be explained: what circulation is being supported now, what remains unresolved and what the next assessment will consider. A stage of treatment is not automatically a complete anatomical cure. NHLBI selected congenital treatment categories, March24,2022.
Inflammatory disease and rhythm disorders need different treatment decisions. Children with suspected severe myocarditis need paediatric cardiac and critical-care expertise. The cited staff guideline does not establish that every child needs steroids, immunoglobulin or the same intensive-care treatment. Evelina/Royal Brompton actual staff myocarditis/cardiomyopathy guideline, March2024 version1,2pages.
Kawasaki treatment may include prescribed aspirin and intravenous therapy under the hospital team. Do not give aspirin to a child as a general fever remedy or heart-prevention strategy. Follow-up is guided by whether the coronary vessels were affected. NHS Kawasaki disease, February19,2026.
Feeding, growth, swallowing and activity
Feeding uses energy. A child with cardiac or breathing difficulty may tire during meals or take less than expected. The problem can involve swallowing safety as well as calorie intake; some children need help from a dietitian and a speech and language therapist. Evelina/GSTT feeding/swallowing guide, December2025 version2,3pages.
Aspiration means food or drink enters the airway. It may cause coughing or choking, but can also be less obvious. The specialist source describes selected assessment, including observation and sometimes a swallow study. Families should not change textures, concentrate feeds or copy another child’s tube-feeding plan without the team. Evelina/GSTT feeding/swallowing guide, December2025 version2,3pages.
Physical activity should fit the diagnosis, medicines, implanted devices and current condition. Ask for guidance about school sport and activities the child enjoys, rather than assuming either unrestricted competitive sport or complete inactivity is necessary. NHLBI selected congenital continuing care, March24,2022.
No independently screened supplement regimen is established here to close a defect, prevent dangerous rhythms or replace cardiac medicine. A clinician-confirmed nutritional need is a different indication from a retail “children’s heart health” promise.
Development, learning and meaningful care goals
A useful plan names the problem it is addressing: blood flow, rhythm, symptoms, feeding or development. The goal of a cardiac procedure is different from the goal of swallowing therapy. Combining all outcomes into “stronger heart health” makes the plan harder to evaluate.
Learning and developmental concerns deserve attention. The Evelina leaflet explains that individual prediction is uncertain and a prenatal structural scan cannot tell exactly how a child’s learning or behaviour will develop. A congenital diagnosis should not be treated as a fixed forecast of abilities. Evelina/GSTT selected neurodevelopment uncertainty, November2023 version1,2pages.
Raise concerns about language, attention, learning or behaviour with the care team and school. Ask what assessment and support are appropriate for the child’s actual needs. Uncertainty about predicting development is not a reason to dismiss a difficulty that is already affecting everyday life. Evelina/GSTT selected neurodevelopment uncertainty, November2023 version1,2pages.
A good result after treatment is welcome but does not prove that every later symptom is harmless. Keep the current follow-up plan and ask what complications it is intended to detect. Clinical education here does not certify the sponsorship of every original intervention trial.
Emergency signs and complications to report
Call the local emergency service for sudden blue or grey lips or skin, severe breathing difficulty, collapse, confusion or a child who is unusually limp or unresponsive. Colour changes can be harder to recognise on darker skin; lips, gums and palms can provide additional clues. NHS congenital heart disease, December11,2025.
A fast heartbeat associated with chest discomfort, marked breathlessness or feeling faint needs urgent assessment. A wearable notification or a pulse count cannot identify the rhythm or choose treatment. Avoid trying adult manoeuvres on a baby without specific professional instructions. NHS SVT selected all-age rhythm context, June12,2024.
Tell the team about feeding decline, repeated choking, persistent wet cough, difficulty gaining weight or unusual tiring. These signs are not specific to a heart condition, but need assessment rather than being dismissed as fussiness. Evelina/GSTT feeding/swallowing guide, December2025 version2,3pages.
Procedures can have complications, including bleeding, infection and vessel injury with catheter treatment. Ask about the proposed procedure’s own risks and aftercare. A general success story cannot provide a personal risk estimate. NHLBI selected congenital treatment categories, March24,2022.
Paediatric medicines and procedure coordination
Children’s heart medicines need an exact prescription and paediatric review. A familiar drug name does not make an adult dose suitable. The NHS digoxin source explicitly limits child use to specialist recommendation; its2023 review is overdue, so no dose or schedule is imported here. NHS digoxin specialist paediatric suitability, March22,2023; review overdue.
Bring all prescriptions, medicines bought without a prescription and supplements to a pharmacy or cardiac-team review. Tell the team about changed feeding, vomiting, illness or difficulty administering a medicine; ask for instructions rather than improvising a replacement dose.
Before another procedure, tell the treating clinician about the child’s cardiac diagnosis and devices. Dental care also matters. This does not mean every child needs antibiotics before every dental visit; prevention depends on the diagnosis and the planned procedure. NHLBI selected congenital continuing care, March24,2022.
Screening reassurance and activity assumptions to avoid
Avoid interpreting a passed newborn screen as permanent reassurance. Screening can miss defects, and later symptoms require their own assessment. A home oxygen meter is not a substitute for evaluation of an unwell baby. CDC newborn cardiac screening explanation and limits, December15,2025.
Avoid imposing lifelong sport restrictions from a broad diagnosis label. Equally, a general claim that exercise is healthy does not clear competitive or demanding activity. Obtain advice that reflects the child’s current condition. NHLBI selected congenital continuing care, March24,2022.
Avoid assuming the parent caused the disease or that every sibling has the same condition. Genetic testing, where considered, should answer a defined question and include an explanation of its limits. NHLBI congenital diagnosis, March24,2022.
Family plans, school support and transition to adult care
Ask for a written summary of the diagnosis, procedures, medicines, warning signs and contacts. Agree what school or nursery staff need to know and who can explain the care plan. This guide supplies no personal dose, feeding protocol or exercise prescription.
Transition to adult heart services is a process rather than a single birthday. The Evelina source describes education about the condition, past treatment, future care and lifestyle questions, with involvement from both child and adult teams. Exact transfer ages and services vary locally. Evelina/GSTT transition to adult heart services; clinical date unclosed.
As the young person grows, include them in explanations and decisions at a pace that fits their development. Ask how to arrange private questions and family support under local confidentiality rules; the source’s blanket legal wording is not adopted as a worldwide rule. Evelina/GSTT transition to adult heart services; clinical date unclosed.
When moving home or starting further education, arrange a handover and a local contact route. Keep records accessible so continuing care does not depend on remembering a childhood operation name. Evelina/GSTT transition to adult heart services; clinical date unclosed.
Laboratory findings versus children’s clinical outcomes
Animal and laboratory work can investigate heart development, muscle inflammation or device engineering. It cannot predict an individual child’s future abilities, establish a safe paediatric dose or show that a retail supplement improves clinical outcomes. No animal or in-vitro result supplies this guide’s independent clinical verdict. Manufacturer-funded or supplied-product outcome evidence would be Tier4/GradeD for financial independence; strong methods do not remove that financial interest.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 18 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
These are selected clinical education and care-coordination sources. National NHS and US agencies have separately traced public routes; Evelina/Royal Brompton material belongs to GSTT, whose own private/research/charity/commercial channels were checked. Individual authors and original drug/device/feeding-product trial finances remain unclosed, so no independent efficacy ranking or numerical prognosis is established.
The clinical subject has no single corporate owner; medicines, devices and supplements have separate commercial ownership and financial interests. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS congenital heart disease, December11,2025 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original read selectively. Adult pulse thresholds, general prognosis, generic congenital digoxin/oxygen claims, universal contraindications or medicine schedules excluded; digoxin reviewMarch2026overdue. Public-care accuracy incentive; simplified age/diagnosis coverage and original drug/author finances unclosed. Role: Selected congenital definition and paediatric emergency signs. |
| NHLBI congenital diagnosis, March24,2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actualMarch2022 original body read; public educational accuracy incentive, dated simplification and original contributor/trial funding gaps. Selected diagnostic, procedural or continuing-care categories only; universal spontaneous improvement, fixed vaccine/medicine schedules, repaired-heart guarantees, survival numbers and surgery eligibility rules excluded. Role: Distinct structural, rhythm and selected genetic investigation roles. |
| NHLBI selected congenital treatment categories, March24,2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actualMarch2022 original body read; public educational accuracy incentive, dated simplification and original contributor/trial funding gaps. Selected diagnostic, procedural or continuing-care categories only; universal spontaneous improvement, fixed vaccine/medicine schedules, repaired-heart guarantees, survival numbers and surgery eligibility rules excluded. Role: Selected observation, catheter, surgery and support categories. |
| NHLBI selected congenital continuing care, March24,2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | C provisional — actualMarch2022 original body read; public educational accuracy incentive, dated simplification and original contributor/trial funding gaps. Selected diagnostic, procedural or continuing-care categories only; universal spontaneous improvement, fixed vaccine/medicine schedules, repaired-heart guarantees, survival numbers and surgery eligibility rules excluded. Role: Activity, emotional health, prevention and continuing-care context. |
| CDC newborn cardiac screening explanation and limits, December15,2025 | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 1 public education provisional; gift, donor and full page-specific chain unresolved. | B provisional — actualDecember2025 original read for screening limits. Public-health accuracy incentive; policy/outcome trials and full contributors/backers not cleared. No mortality percentage or negative-screen reassurance adopted. Role: Passed/failed oxygen-screen interpretation limits. |
| Evelina/GSTT feeding/swallowing guide, December2025 version2,3pages | Separate GSTT provider; own2025–26 financial routes include NHS, private, research/education, charity and commercial channels. Specific leaflet allocation, named staff interests and complete underlying study/supplier chains unclosed. National NHS-only finances do not substitute. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | C provisional — actual original read for selected attributed care context. Specialist/public-care accuracy incentive with service/research interests and unclosed author/trial finance. Fixed schedules, personal feeding protocols, efficacy rates and outcome guarantees excluded. Role: Feeding workload, swallowing/aspiration and specialist assessment. |
| Evelina/GSTT selected neurodevelopment uncertainty, November2023 version1,2pages | Separate GSTT provider; own2025–26 financial routes include NHS, private, research/education, charity and commercial channels. Specific leaflet allocation, named staff interests and complete underlying study/supplier chains unclosed. National NHS-only finances do not substitute. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | C provisional — actual original read for selected attributed care context. Specialist/public-care accuracy incentive with service/research interests and unclosed author/trial finance. Fixed schedules, personal feeding protocols, efficacy rates and outcome guarantees excluded. Role: Selected developmental uncertainty and limits of prenatal prediction. Dated2023 uncertainty context only; no assertion of no possible developmental support or individual future prediction. |
| Evelina/GSTT transition to adult heart services; clinical date unclosed | Separate GSTT provider; own2025–26 financial routes include NHS, private, research/education, charity and commercial channels. Specific leaflet allocation, named staff interests and complete underlying study/supplier chains unclosed. National NHS-only finances do not substitute. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider clinical education; mixed institutional funding disclosed, page/author chain unclassified. | C provisional — actual original read for selected attributed care context. Specialist/public-care accuracy incentive with service/research interests and unclosed author/trial finance. Fixed schedules, personal feeding protocols, efficacy rates and outcome guarantees excluded. Role: Stages, education, continuity and moving-home handover; fixed ages/legal rules excluded. Full review date unclosed. Fixed transfer ages, parent consent rights and unconditional confidentiality claims are local/legal context not adopted as worldwide rules. |
| Evelina/Royal Brompton actual staff myocarditis/cardiomyopathy guideline, March2024 version1,2pages | Separate GSTT provider; own2025–26 financial routes include NHS, private, research/education, charity and commercial channels. Specific leaflet allocation, named staff interests and complete underlying study/supplier chains unclosed. National NHS-only finances do not substitute. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 2 provider staff clinical guidance, provisional; original author/drug-trial chain unclassified. | C provisional — actual original read for selected attributed care context. Specialist/public-care accuracy incentive with service/research interests and unclosed author/trial finance. Fixed schedules, personal feeding protocols, efficacy rates and outcome guarantees excluded. Role: Acquired myocarditis/cardiomyopathy distinctions and specialist urgency; staff protocols excluded. ActualMarch2024 source names Cheang/Alasnag/Lillie and internal approvals; full financial declarations not supplied. ICU doses, home resuscitation/fluid protocols, diagnostic sensitivity, most-common ranking, IVIG/steroid efficacy and numerical prognosis excluded. |
| NHS Kawasaki disease, February19,2026 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | B provisional — actual dated original read for selected definitions, warning signs or care coordination. Public-education accuracy incentive; age-specific generalizations and complete contributor/original-trial financial chain remain unresolved. Role: Acquired vessel inflammation, assessment and clinician-only child aspirin. |
| NHS SVT selected all-age rhythm context, June12,2024 | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original read selectively. Adult pulse thresholds, general prognosis, generic congenital digoxin/oxygen claims, universal contraindications or medicine schedules excluded; digoxin reviewMarch2026overdue. Public-care accuracy incentive; simplified age/diagnosis coverage and original drug/author finances unclosed. Role: All-age rhythm presentation and selected assessment context; adult pulse thresholds excluded. |
| NHS digoxin specialist paediatric suitability, March22,2023; review overdue | National NHS England institutional channels and editorial policy: see own2025–26 accounts and no-advertising/no-corporate-sponsorship policy. Page allocation, named reviewers and original pregnancy/drug-study finances remain unresolved. Provider trust finance is separate. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 1 public education provisional; supporting trial/author finance unclassified. | C provisional — actual dated original read selectively. Adult pulse thresholds, general prognosis, generic congenital digoxin/oxygen claims, universal contraindications or medicine schedules excluded; digoxin reviewMarch2026overdue. Public-care accuracy incentive; simplified age/diagnosis coverage and original drug/author finances unclosed. Role: Specialist-only child medicine indication; dated review gap. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHLBI congenital heart defects overview, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| CDC original FY2026 operating plan | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC dated2016 gift authority,2022 editorial review | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| CDC actual Atlanta contact and public-site provenance | CDC/HHS federal budget authority and public transfers in FY2026 operating plan. Separate gift authority permits donations, bequests, in-kind support and CDC Foundation transfers with conflict review. These permitted routes do not prove a private gift financed this page. Named donors, page allocation and author/original-study finances unresolved. | United States; CDC Atlanta, Georgia, federal public-health jurisdiction. Archived surveillance handbook has international partner links; complete partner and backer financial chains not cleared. | Tier 3 institutional finance, policy or contact self-disclosure. | B provisional for documented finance routes and location. Gift policy is dated2016 with2022 editorial review; actual donors, implementation, page allocations and individual independence not audited. Financial provenance only. |
| Guy’s and St Thomas’ audited2025–26 accounts | Guy’s and St Thomas’ NHS Foundation Trust: actual audited2025–26 accounts discloses NHS commissioners, private patients, research/education, charitable and commercial income. Actual institutional partnership names include Johnson & Johnson Managed Services, Diaverum and ActiveCareGroup; no attribution to this leaflet or complete contributor/trial chain established. | United Kingdom; adult and paediatric provider sites London and Harefield, England; service-specific pathway. | Tier 3 institutional financial self-report. | B provisional — actual audited institutional report, no full individual allocation. Financial provenance only. |
Frequently asked questions
Can a child have heart disease after a normal newborn screen? Yes. Screening cannot exclude every defect, and acquired conditions can occur later.
Does every murmur mean a serious defect? A sound heard by a clinician is a finding; assessment determines its significance.
Are feeding difficulties always caused by the heart? No. Cardiac workload, swallowing, breathing and other causes may need assessment.
Can children with heart disease attend school and be active? The plan should support participation according to the actual condition, without automatic unrestricted sport or blanket exclusion.
Does childhood surgery end adult care? Not necessarily. Ask about the ongoing congenital review and transition plan.
Sources and funding notes
- NHS congenital heart disease, December11,2025 — Selected congenital definition and paediatric emergency signs.
- NHLBI congenital diagnosis, March24,2022 — Distinct structural, rhythm and selected genetic investigation roles.
- NHLBI selected congenital treatment categories, March24,2022 — Selected observation, catheter, surgery and support categories.
- NHLBI selected congenital continuing care, March24,2022 — Activity, emotional health, prevention and continuing-care context.
- CDC newborn cardiac screening explanation and limits, December15,2025 — Passed/failed oxygen-screen interpretation limits.
- Evelina/GSTT feeding/swallowing guide, December2025 version2,3pages — Feeding workload, swallowing/aspiration and specialist assessment.
- Evelina/GSTT selected neurodevelopment uncertainty, November2023 version1,2pages — Selected developmental uncertainty and limits of prenatal prediction.
- Evelina/GSTT transition to adult heart services; clinical date unclosed — Stages, education, continuity and moving-home handover; fixed ages/legal rules excluded.
- Evelina/Royal Brompton actual staff myocarditis/cardiomyopathy guideline, March2024 version1,2pages — Acquired myocarditis/cardiomyopathy distinctions and specialist urgency; staff protocols excluded.
- NHS Kawasaki disease, February19,2026 — Acquired vessel inflammation, assessment and clinician-only child aspirin.
- NHS SVT selected all-age rhythm context, June12,2024 — All-age rhythm presentation and selected assessment context; adult pulse thresholds excluded.
- NHS digoxin specialist paediatric suitability, March22,2023; review overdue — Specialist-only child medicine indication; dated review gap.
- NHS England actual audited2025–26 accounts — National website actual current financial provenance.
- NHLBI congenital heart defects overview, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- CDC original FY2026 operating plan — Financial provenance only.
- CDC dated2016 gift authority,2022 editorial review — Financial provenance only.
- CDC actual Atlanta contact and public-site provenance — Financial provenance only.
- Guy’s and St Thomas’ audited2025–26 accounts — Financial provenance only.
The selected clinical originals and institutional financial sources were opened, with access-limited author reports and corrections identified explicitly. Actual NHS December2025 congenital, February2026 Kawasaki, June2024 SVT and datedMarch2023 digoxin suitability originals read. Actual NHLBI March2022 diagnostic/treatment/living bodies, CDC December2025 screening, Evelina December2025 feeding and November2023 developmental PDFs, transition page and March2024 staff myocarditis guideline read. National NHS/NHLBI/CDC and separate GSTT current financial provenance traced. Adult pulse criteria, self-feeding changes, fixed drug/vaccine/surgery/transition schedules, unconditional confidentiality, IVIG/steroid efficacy, numeric outcome/sensitivity claims and developmental predictions excluded. No website mutation. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.